Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

Date: March 21, 2022 Issue #:  1646Summary:  Faricimab-svoa (Vabysmo– Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available i n the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: aflibercept Age-related macular degeneration Avastin Beovu Bevacizumab brolucizumab Byooviz Eye Eylea faricimab Lucentis Ranibizumab Susvimo Vabysmo Source Type: research